Amphista enters two collaborations for protein degrading therapeutics

Amphista enters two collaborations for protein degrading therapeutics
6 May 2022
European Pharmaceutical Manufacturer – View full story

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Amphista Lands Megadeals to Smash Cancer using Protein Degradation
6 May 2022
Heal Security – View full story

Amphista and BMS partner to develop protein degradation therapies

Amphista and BMS partner to develop protein degradation therapies
6 May 2022
Pharma Advancement – View full story

Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera

Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
5 May 2022
Scrip – View full story

BMS, Merck Partner with Amphista Therapeutics to Develop Targeted Protein Degraders

BMS, Merck Partner with Amphista Therapeutics to Develop Targeted Protein Degraders
5 May 2022
Precision Oncology News – View full story

Amphista and BMS partner to develop protein degradation therapies

Amphista and BMS partner to develop protein degradation therapies
5 May 2022
Pharmaceutical Technology – View full story

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Amphista Lands Megadeals to Smash Cancer using Protein Degradation
5 May 2022
Labiotech.eu – View full story

Two Pharma Giants Link Up With Amphista on Protein Degradation Projects

Two Pharma Giants Link Up With Amphista on Protein Degradation Projects
5 May 2022
FDANews – View full story
Article requires subscription to view full text

Multi-billion dollar vote of confidence in UK protein specialist

Multi-billion dollar vote of confidence in UK protein specialist
5 May 2022
The Pharma Letter – View full story

Dundee’s Amphista strikes collaboration deals that could be worth billions

Dundee’s Amphista strikes collaboration deals that could be worth billions
5 May 2022
The Herald Scotland – View full story